Clinical trials: Clostridium Difficile Infection
Clostridioides Difficile Infection, Recurrent Infection
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year.
- Trial name
- LIVEDIFF (NCT06306014)
- Testing
- EXL01
- Where
- 10 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Faecal microbiota transplantation (FMT) is used for Clostridioides difficile infection (CDI) as part of an quality improvement initiative and conducted within the framework of Center for Faecal Microbiota Transplantation at…
- Trial name
- CEFTA (NCT03712722)
- Testing
- Faecal microbiota transplantation (FMT)
- Where
- Denmark
- Volunteers
- 2,000 people
- Sponsor
- University of Aarhus
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
Clostridioides difficile (CD) infection (CDI) is a global health threat with an urgent need for new treatment strategies. Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection…
- Trial name
- EarlyFMT (NCT04885946)
- Testing
- Fecal microbiota transplantion (FMT)
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Christian Lodberg Hvas
Clostridium Difficile Infection Recurrence
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Single-arm trial to evaluate the safety and efficacy of ACX-362E [ibezapolstat] in patients with recurrent C. difficile infection (CDI).
- Trial name
- NCT07513285
- Testing
- Ibezapolstat
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Acurx Pharmaceuticals Inc.
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile
Animal-Assisted Visitation Program Chlorhexidine Trial
Hospital-based Animal-Assisted visitation programs are important complementary therapies, but concerns with infection control may challenge the sustainability of these programs.
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
- Trial name
- NCT04171817
- Testing
- Chlorhexidine
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Clostridioides Difficile Infection
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response…
- Trial name
- Ri-CoDIFy 1 (NCT03595553)
- Testing
- Ridinilazole, Vancomycin
- Where
- 149 sites in United States, Argentina and 12 more
- Volunteers
- 759 people
- Sponsor
- Summit Therapeutics
Clostridium Difficile Infection
A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose exploration cohorts.
- Trial name
- NCT07649096
- Testing
- FZ002
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
- Trial name
- PRISM (NCT07285213)
- Testing
- AZD5148
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Clostridioides Difficile Infection
LMN-201 for Prevention of C. Difficile Infection Recurrence
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
- Trial name
- NCT05330182
- Testing
- LMN-201
- Where
- 15 sites in United States
- Volunteers
- 375 people
- Sponsor
- Lumen Bioscience, Inc.
Clostridium Difficile, Clostridium Difficile Infections
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
- Trial name
- RESTORATiVE303 (NCT06237452)
- Testing
- VE303
- Where
- 215 sites in United States, Australia and 22 more
- Volunteers
- 852 people
- Sponsor
- Vedanta Biosciences, Inc.
Clostridium Difficile Infection, Health Care Associated Infection
Natural History of Clostridioides Difficile Infection
Aim: To investigate if host factors, such as composition and diversity of intestinal microbiota and/or genetic determinants, are associated with a higher risk of recurrence of Clostridioides difficile infection (CDI).
- Conditions
- Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection
- Trial name
- NCT04801862
- Where
- 15 sites in Spain
- Volunteers
- 750 people
- Sponsor
- Hospital Universitario de Valme
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection
This is a single-center, open-label study for safety and feasibility of IMT in patients undergoing colonic surgery. After consent, individuals of the ages of 18-75 with a history of diverticulitis or sigmoid colon cancer will be…
- Trial name
- NCT06370884
- Testing
- IMT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Recurrent Clostridioides Difficile Infection, Colonic Surgery
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
This Phase 1 pilot clinical trial that will evaluate the initial safety and feasibility of orally administered preparation of fecal microbiota (MTP-101P) in patients undergoing colon resection.
- Trial name
- NCT06692179
- Testing
- Orally administered preparation of fecal microbiota (MTP-101P)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Minnesota
Clostridium Difficile Infections
Safety Registry of a Fecal Microbiota Transplant Cohort
Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection.
- Trial name
- COSMIC-FMT (NCT06311006)
- Where
- France
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Clostridioides Difficile Infection
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin…
- Trial name
- FENDER (NCT05266807)
- Testing
- oral capsulized Fecal Microbiota Transplantation, Vancomycin or Fidaxomicin
- Where
- 8 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- Benoit Guery
Clostridioides Difficile Infection
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling.
- Trial name
- NCT07613645
- Testing
- Health counseling sessions, Diet (control diet), Diet (experimental diet)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode.
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease
- Trial name
- SPORES-V (NCT06979609)
- Testing
- Oral Vancomycin Prophylaxis
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Clostridioides Difficile Infection Recurrence
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of this study is to map the risk of having a C.
- Trial name
- NCT07250724
- Testing
- Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bactolife A/S